TROV - TrovaGene, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.81
+0.01 (+1.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.80
Open0.78
Bid0.75 x 1100
Ask0.83 x 1800
Day's Range0.77 - 0.82
52 Week Range0.65 - 12.96
Volume572,014
Avg. Volume1,068,222
Market Cap14.328M
Beta-0.08
PE Ratio (TTM)N/A
EPS (TTM)-3.95
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.75
Trade prices are not sourced from all markets
  • Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial
    PR Newswire3 days ago

    Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial

    All three patients in the cohort successfully completed treatment with Onvansertib at 18 mg/m2, administered orally, once daily, on days 1-5 of the treatment cycle, in combination with LDAC and the combination was well tolerated. The Safety Review Committee (SRC) has recommended escalating to the next dose level of Onvansertib at 27 mg/m2 (approximately a 50% increase) in combination with LDAC. Additionally, two patients in the three-patient cohort of Onvansertib at 18 mg/m2 in combination with decitabine have also successfully completed at least one cycle of treatment and recruitment of the third patient to complete this cohort is in process.

  • Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075
    PR Newswire4 days ago

    Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075

    SAN DIEGO, Aug. 15, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapies for the treatment of leukemias, lymphomas and solid tumor cancers, announced today that the United States Adopted Name (USAN) Council has approved "Onvansertib" (pronounced on-van-ser-tib) as the nonproprietary (generic) name for its drug candidate, PCM-075.  Onvansertib is a first-in-class, 3rd generation, highly selective, oral Polo Like Kinase 1 (PLK1) inhibitor, that is designed to target and inhibit cancer cell division (mitosis). "Assignment of a unique generic name is a very meaningful step forward for our drug candidate, PCM-075," said Dr. Thomas Adams, Executive Chairman of Trovagene.

  • Trovagene (TROV) Reports Q2 Loss, Tops Revenue Estimates
    Zacks15 days ago

    Trovagene (TROV) Reports Q2 Loss, Tops Revenue Estimates

    Trovagene (TROV) delivered earnings and revenue surprises of -33.33% and 12.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press15 days ago

    Trovagene: 2Q Earnings Snapshot

    The San Diego-based company said it had a loss of 88 cents per share. Losses, adjusted for non-recurring costs, were 44 cents per share. The molecular diagnostic company posted revenue of $112,000 in the ...

  • Trovagene Announces Second Quarter 2018 Highlights and Financial Results
    PR Newswire15 days ago

    Trovagene Announces Second Quarter 2018 Highlights and Financial Results

    SAN DIEGO , Aug. 3, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of leukemias, lymphomas and solid ...

  • Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene's Investigational Cancer Drug
    PR Newswire18 days ago

    Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene's Investigational Cancer Drug

    SAN DIEGO, Aug. 1, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of leukemias/lymphomas and solid tumor cancers, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending PCM-075 for designation as an orphan medicinal product for the treatment of Acute Myeloid Leukemia (AML).  PCM-075 is a first-in-class, 3rd generation, highly selective, oral Polo Like Kinase 1 (PLK1) inhibitor, that is designed to target cell division (mitosis).

  • ACCESSWIRE23 days ago

    Breakfast Technical Briefing on TrovaGene and Three Other Additional Medical Research Stocks

    LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on TROV sign up now at www.wallstequities.com/registration. WallStEquities.com draws investors' attention to the Medical Laboratories and Research category, which includes companies that focus on performing various tests on patients that give them information on patients' health. Lined up for review are the following equities: Foundation Medicine Inc. (NASDAQ: FMI), NeoGenomics Inc. (NASDAQ: NEO), Neuronetics Inc. (NASDAQ: STIM), and TrovaGene Inc. (NASDAQ: TROV).

  • Trovagene Presents Outlook for Second Half of 2018
    PR Newswirelast month

    Trovagene Presents Outlook for Second Half of 2018

    SAN DIEGO, July 9, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today provided an update on key value-creating milestones for the second half of 2018 and a review of its year-to-date achievements. "As a team, we achieved a number of key milestones in the first half of 2018 and we continue to execute on our business plan and to advancing our clinical development program in the second half of 2018. Looking ahead to the second half of 2018, the Company's Board of Directors is undertaking a search for a new CEO, who has the relevant therapeutic and drug development experience to lead Trovagene into its next stage.

  • Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML
    PR Newswire2 months ago

    Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML

    Additional pharmacodynamic data supports inhibition of PLK1 in leukemic cells as measured by pTCTP in its Phase 1b /2 trial in Acute Myeloid Leukemia (AML) SAN DIEGO , June 27, 2018 /PRNewswire/ -- Trovagene, ...

  • TrovaGene Enters Oversold Territor
    Zacks2 months ago

    TrovaGene Enters Oversold Territor

    TrovaGene Enters Oversold Territor

  • Trovagene Announces Leadership Change
    PR Newswire2 months ago

    Trovagene Announces Leadership Change

    William Welch has resigned as CEO and Director Dr. Thomas Adams, Chairman of the Board Appointed Interim CEO SAN DIEGO , June 22, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology ...

  • Trovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® in Patients with mCRPC
    PR Newswire2 months ago

    Trovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® in Patients with mCRPC

    SAN DIEGO, June 21, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced they have received Institutional Review Board (IRB) approval from Dana-Farber/Harvard Cancer Center and its Phase 2 clinical trial of PCM-075 in combination with Zytiga® (abiraterone acetate) and prednisone in metastatic Castration-Resistant Prostate Cancer (mCRPC) is officially activated and recruiting patients. The trial is being conducted by Beth Israel Deaconess Medical Center (BIDMC), Dana-Farber Cancer Institute (Dana-Farber), and Massachusetts General Hospital Cancer Center (MGH).

  • Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial
    PR Newswire2 months ago

    Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial

    Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with decitabine in dose-escalation phase of trial SAN DIEGO , June 15, 2018 /PRNewswire/ -- Trovagene, ...

  • Trovagene, Inc. Announces Closing of $18 Million Public Offering
    PR Newswire2 months ago

    Trovagene, Inc. Announces Closing of $18 Million Public Offering

    SAN DIEGO, June 12, 2018 /PRNewswire/ -- Trovagene, Inc. (TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced the closing of its previously announced underwritten public offering for total gross proceeds of $18,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consisted of (i) Class A Units consisting of an aggregate of 9,140,000 shares of our common stock and warrants to purchase an aggregate of 9,140,000 shares of common stock, at a public offering price of $1.00 per Class A Unit, and (ii) Class B Units consisting of 8,860 shares of our Series B Convertible Preferred Stock, with a stated value of $1,000, and convertible into an aggregate of 8,860,000 shares of common stock, and warrants to purchase an aggregate of 18,000,000 shares of common stock, at a public offering price of $1,000 per Class B Unit.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Acorda Therapeutics and TrovaGene

    NEW YORK, NY / ACCESSWIRE / June 11, 2018 / Acorda Therapeutics was seeing big gains on Friday after Wall Street learned that the company's lawyers had try to save previously invalidated patents for its ...

  • TrovaGene Stock Fell 48% on June 8 after Pricing Announcement
    Market Realist2 months ago

    TrovaGene Stock Fell 48% on June 8 after Pricing Announcement

    TrovaGene (TROV) is a clinical-stage oncology therapeutics company. TrovaGene announced the pricing of the underwritten public offering of 18 million shares of its common stock on June 7. Following the announcement, the stock price decreased ~48% to the closing price of $0.92 on June 8.

  • TrovaGene (TROV) Enters Oversold Territory
    Zacks2 months ago

    TrovaGene (TROV) Enters Oversold Territory

    TrovaGene, Inc. (TROV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

  • Trovagene, Inc. Announces Pricing of $18 Million Public Offering
    PR Newswire2 months ago

    Trovagene, Inc. Announces Pricing of $18 Million Public Offering

    SAN DIEGO , June 7, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor ...

  • Trovagene, Inc. Announces Reverse Stock Split
    PR Newswire3 months ago

    Trovagene, Inc. Announces Reverse Stock Split

    SAN DIEGO, May 31, 2018 /PRNewswire/ -- Trovagene, Inc. (TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, announced today, a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 12, effective June 1, 2018 (the "Effective Date"). The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market. The new CUSIP number for the common stock following the reverse split will be 897238 408.

  • Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Myeloid Leukemia
    PR Newswire3 months ago

    Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Myeloid Leukemia

    SAN DIEGO, May 17, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced the completion of the first dose cohort in its Phase 1b/2 clinical trial of PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) Inhibitor, in combination with LDAC, in Acute Myeloid Leukemia (AML). Three patients were treated with PCM-075 at 12 mg/m2, administered orally, once daily, on days 1-5 of the treatment cycle, in combination with LDAC.  Patients eligible for Phase 1b have relapsed or refractory disease and may have received as many as three prior regimens for treatment of their AML.

  • Does TrovaGene Inc’s (NASDAQ:TROV) Past Performance Indicate A Stronger Future?
    Simply Wall St.3 months ago

    Does TrovaGene Inc’s (NASDAQ:TROV) Past Performance Indicate A Stronger Future?

    Measuring TrovaGene Inc’s (NASDAQ:TROV) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations,Read More...

  • Associated Press3 months ago

    Trovagene: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 9 cents per share. The molecular diagnostic company posted revenue of $100,000 in the period. In the final minutes of trading on Tuesday, the company's ...

  • Trovagene Announces First Quarter 2018 Highlights and Financial Results
    PR Newswire3 months ago

    Trovagene Announces First Quarter 2018 Highlights and Financial Results

    SAN DIEGO , May 8, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapies to treat hematologic and solid tumor cancers, today ...

  • Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine
    PR Newswire4 months ago

    Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine

    Methodology to assess changes in leukemic cells, genomic alterations and pTCTP status for Phase 1b /2 Clinical Trial of PCM-075. Update on clinical trial recruitment. SAN DIEGO , April 17, 2018 /PRNewswire/ ...

  • Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML)
    PR Newswire4 months ago

    Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML)

    Combination of PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) inhibitor, and Quizartinib resulted in 97% tumor growth inhibition and regression in FLT3 AML model SAN DIEGO , April 16, 2018 /PRNewswire/ ...